Get Your Personalized Supplement StackSupplement Stack Quiz

Ursodeoxycholic acid

Also known as: UDCA, Ursodiol, Ursodeoxycholate, Ursodeoxycholic acid

Overview

Ursodeoxycholic acid (UDCA) is a naturally occurring hydrophilic secondary bile acid found in small quantities in human bile and more abundantly in bear bile. For pharmaceutical use, it is synthetically produced. UDCA is primarily utilized in the treatment of cholestatic liver diseases, such as primary biliary cholangitis, and nonalcoholic fatty liver disease (NAFLD), as well as pediatric cholestasis. It is also being investigated for potential cardiometabolic benefits. UDCA is characterized by its hydrophilicity, lower cytotoxicity compared to other bile acids, and its ability to modulate bile acid composition, liver enzyme levels, and inflammation. Research on UDCA is extensive, with numerous randomized controlled trials (RCTs) and meta-analyses supporting its efficacy, particularly in improving liver enzymes and alleviating symptoms in cholestatic conditions. The available evidence is considered moderate to high quality.

Benefits

Ursodeoxycholic acid (UDCA) offers several evidence-based benefits, primarily in liver health. It significantly reduces liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) in patients with Nonalcoholic Fatty Liver Disease (NAFLD), with highly statistically significant improvements (p ≤ 0.0001 for ALT and GGT, p = 0.0009 for AST). This indicates a strong hepatoprotective effect. In children with cholestasis, UDCA has been shown to improve symptoms and biochemical markers, with a 24% increased likelihood of symptom improvement compared to controls (RR 1.24, 95% CI 1.18 to 1.29). These reductions in liver enzymes are clinically relevant markers of improved liver injury. While less consistent, some evidence suggests potential secondary benefits in cardiometabolic risk factors, including improvements in body mass index (BMI) and diastolic blood pressure (DBP), though effects on systolic blood pressure (SBP) and weight are inconsistent. The time course for benefits varies, with improvements typically observed within weeks to months of therapy, depending on the condition and dosage.

How it works

Ursodeoxycholic acid (UDCA) exerts its therapeutic effects primarily by altering the composition of the bile acid pool. It replaces more hydrophobic and cytotoxic bile acids, thereby reducing their damaging effects on hepatocytes (liver cells). This mechanism helps protect the liver from injury. UDCA also promotes bile flow, a process known as choleresis, which aids in the removal of harmful substances from the liver and protects cholangiocytes (bile duct cells). Furthermore, UDCA modulates liver enzyme activity and reduces inflammation within the liver. It influences bile acid signaling pathways, which play a role in metabolism and immune responses, although UDCA is a weak ligand for key bile acid receptors like FXR and TGR5. After oral administration, UDCA is absorbed in the intestine, undergoes enterohepatic circulation, and accumulates in the liver.

Side effects

Ursodeoxycholic acid (UDCA) is generally well-tolerated and has a favorable safety profile. The most common side effects, affecting more than 5% of users, are gastrointestinal symptoms such as diarrhea and abdominal discomfort, particularly noted in children (incidence around 10.6%). Uncommon side effects, occurring in 1-5% of individuals, include mild elevations in liver enzymes or rare allergic reactions. Very rare side effects, affecting less than 1% of users, can include severe hypersensitivity reactions or, paradoxically, a worsening of cholestasis in isolated cases. Drug interactions are minimal, but caution is advised when co-administering with medications that affect bile acid metabolism or liver function. UDCA is contraindicated in individuals with known hypersensitivity to the compound and in patients with complete biliary obstruction. For special populations, pediatric dosing requires careful monitoring, and its safety during pregnancy and lactation has not been fully established, warranting caution and medical consultation.

Dosage

The recommended dosage of Ursodeoxycholic acid (UDCA) varies depending on the specific indication, but typical doses for liver diseases range from 10 to 15 mg/kg/day. For conditions like Nonalcoholic Fatty Liver Disease (NAFLD) and cholestasis, an optimal dosage range is generally 13-15 mg/kg/day, usually divided into two or three doses throughout the day. The maximum safe dose is typically up to 20 mg/kg/day; exceeding this limit may increase the risk of side effects without providing additional therapeutic benefit. UDCA should ideally be administered with meals to enhance its absorption and minimize potential gastrointestinal side effects. It is available in oral tablet or capsule forms, with liquid formulations also available for pediatric use. Absorption is improved when taken with fat-containing meals. No specific cofactors are required for its efficacy, but regular monitoring of liver function is recommended during treatment.

FAQs

Is UDCA safe for long-term use?

Yes, UDCA is generally considered safe for long-term use, especially in chronic liver diseases, provided it is taken under medical supervision and regular monitoring.

How soon can liver enzyme improvements be seen?

Improvements in liver enzyme levels are often observed within a few weeks to several months of initiating UDCA therapy, depending on the individual and the specific liver condition.

Can UDCA be used for weight loss or metabolic syndrome?

While some research suggests potential minor benefits on certain cardiometabolic markers, the evidence is inconsistent and limited. UDCA is not recommended as a primary treatment for weight loss or metabolic syndrome.

Are there any major drug interactions?

Few significant drug interactions are known. However, it's always important to consult your healthcare provider about all medications you are taking to avoid potential interactions, especially with drugs affecting liver function or bile acid metabolism.

Does UDCA cure liver diseases?

UDCA improves liver function and symptoms associated with various liver diseases, but it does not typically cure the underlying conditions. It helps manage the disease progression and improve quality of life.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/39022193/ – This meta-analysis of 7 RCTs on UDCA in NAFLD demonstrated significant reductions in ALT, AST, and GGT, indicating its efficacy in improving liver enzyme profiles. The study confirmed robustness through sensitivity analyses but noted heterogeneity and the need for more RCTs.
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0280691 – This systematic review and meta-analysis of 32 RCTs on UDCA for pediatric cholestasis showed symptom improvement and reductions in liver enzymes and bilirubin. It provided moderate quality evidence, highlighting low adverse event incidence despite variable dosing and study designs.
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14311 – This systematic review and meta-analysis confirmed UDCA's consistent hepatoprotective effects across various liver diseases, evidenced by reductions in liver enzymes. It supports UDCA's clinical use, though it suggests further large RCTs are needed to strengthen the evidence.
https://pubmed.ncbi.nlm.nih.gov/39984850/ – This systematic review and meta-analysis investigated UDCA's cardiometabolic effects, finding possible improvements in BMI and DBP but inconsistent effects on SBP and weight. It suggests limited cardiometabolic benefits and calls for more research in this area.